Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Environ Sci Technol ; 58(8): 3974-3984, 2024 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-38306233

RESUMEN

In contaminated water and soil, little is known about the role and mechanism of the biometabolic molecule siderophore desferrioxamine-B (DFO) in the biogeochemical cycle of uranium due to complicated coordination and reaction networks. Here, a joint experimental and quantum chemical investigation is carried out to probe the biomineralization of uranyl (UO22+, referred to as U(VI) hereafter) induced by Shewanella putrefaciens (abbreviated as S. putrefaciens) in the presence of DFO and Fe3+ ion. The results show that the production of mineralized solids {hydrogen-uranium mica [H2(UO2)2(PO4)2·8H2O]} via S. putrefaciens binding with UO22+ is inhibited by DFO, which can both chelate preferentially UO22+ to form a U(VI)-DFO complex in solution and seize it from U(VI)-biominerals upon solvation. However, with Fe3+ ion introduced, the strong specificity of DFO binding with Fe3+ causes re-emergence of biomineralization of UO22+ {bassetite [Fe(UO2)2(PO4)2·8(H2O)]} by S. putrefaciens, owing to competitive complexation between Fe3+ and UO22+ for DFO. As DFO possesses three hydroxamic functional groups, it forms hexadentate coordination with Fe3+ and UO22+ ions via these functional groups. The stability of the Fe3+-DFO complex is much higher than that of U(VI)-DFO, resulting in some DFO-released UO22+ to be remobilized by S. putrefaciens. Our finding not only adds to the understanding of the fate of toxic U(VI)-containing substances in the environment and biogeochemical cycles in the future but also suggests the promising potential of utilizing functionalized DFO ligands for uranium processing.


Asunto(s)
Shewanella putrefaciens , Uranio , Biomineralización , Deferoxamina/metabolismo , Deferoxamina/farmacología , Shewanella putrefaciens/metabolismo , Sideróforos/metabolismo , Sideróforos/farmacología , Uranio/química , Compuestos de Hierro/química
2.
J Appl Microbiol ; 135(2)2024 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-38341275

RESUMEN

AIMS: The study aims to explore antifungal properties of bacillibactin siderophore produced by the plant growth-promoting rhizobacterium (PGPR) Bacillus subtilis against fungal phytopathogens Alternaria porri and Fusarium equiseti isolated from Solanum lycopersicum and Solanum melongena plants. METHODS AND RESULTS: Alternaria porri and F. equiseti were isolated from infected plants of eggplant and tomato, respectively. A plate assay was employed to assess the effect of bacillibactin against the phytopathogens. The antifungal potential of the PGPR was evaluated by estimation of dry fungal biomass, visualization of cellular deformity using compound and scanning electron microscopy, antioxidative enzyme assay and analysis of membrane damage via using lipid peroxidation. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) analysis was employed to investigate changes in intracellular iron content. The impact of bacillibactin on pathogenesis was evaluated by infecting detached leaves of S. lycopersicum and S. melongena plants with both the pathogens and treating the infected leaves with bacillibactin. Leaves were further investigated for ROS accumulation, extent of necrosis and cell death. Our findings revealed significant damage to the hyphal structure of A. porri and F. equiseti following treatment with bacillibactin. Biomass reduction, elevated antioxidative enzyme levels, and membrane damage further substantiated the inhibitory effects of the siderophore on fungal growth. ICP-AES analysis indicates an increase in intracellular iron content suggesting enhanced iron uptake facilitated by bacillibactin. Moreover, application of 1500 µg ml-1 bacillibactin on infected leaves demonstrated a substantial inhibition of ROS accumulation, necrosis, and cell death upon bacillibactin treatment. CONCLUSIONS: This study confirms the potent antagonistic activity of bacillibactin against both the phytopathogens A. porri and F. equiseti growth, supporting its potential as a promising biological control agent for fungal plant diseases. Bacillibactin-induced morphological, physiological, and biochemical alterations in the isolated fungi and pathogen-infected leaves highlight the prospects of bacillibactin as an effective and sustainable solution to mitigate economic losses associated with fungal infections in vegetable crops.


Asunto(s)
Alternaria , Solanum lycopersicum , Solanum , Antifúngicos/farmacología , Especies Reactivas de Oxígeno/metabolismo , Solanum/metabolismo , Sideróforos/farmacología , Productos Agrícolas/metabolismo , Hierro , Necrosis , Enfermedades de las Plantas/prevención & control , Enfermedades de las Plantas/microbiología
3.
Drug Resist Updat ; 72: 101034, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38134561

RESUMEN

Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and mortality of GNB infection, seriously threaten human health globally. Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron carrier cephalosporin that achieves drug accumulation through a unique "Trojan horse" strategy into the bacterial periplasm. It shows high antibacterial activity against multidrug-resistant (MDR) Enterobacteriaceae and MDR non-fermentative bacteria. The application of cefiderocol offers new hope for treating clinical drug-resistant bacterial infections. However, limited clinical data and uncertainties about its resistance mechanisms constrain the choice of its therapeutic use. This review aimed to summarize the clinical applications, drug resistance mechanisms, and co-administration of cefiderocol.


Asunto(s)
Cefiderocol , Infecciones por Bacterias Gramnegativas , Humanos , Sideróforos/farmacología , Sideróforos/uso terapéutico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/microbiología , Bacterias Gramnegativas , Farmacorresistencia Bacteriana Múltiple , Pruebas de Sensibilidad Microbiana
4.
Int J Mol Sci ; 24(9)2023 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-37175772

RESUMEN

Burkholderia pyrrocinia JK-SH007 can effectively control poplar canker caused by pathogenic fungi. Its antifungal mechanism remains to be explored. Here, we characterized the functional role of CysB in B. pyrrocinia JK-SH007. This protein was shown to be responsible for the synthesis of cysteine and the siderophore ornibactin, as well as the antifungal activity of B. pyrrocinia JK-SH007. We found that deletion of the cysB gene reduced the antifungal activity and production of the siderophore ornibactin in B. pyrrocinia JK-SH007. However, supplementation with cysteine largely restored these two abilities in the mutant. Further global transcriptome analysis demonstrated that the amino acid metabolic pathway was significantly affected and that some sRNAs were significantly upregulated and targeted the iron-sulfur metabolic pathway by TargetRNA2 prediction. Therefore, we suggest that, in B. pyrrocinia JK-SH007, CysB can regulate the expression of genes related to Fe-S clusters in the iron-sulfur metabolic pathway to affect the antifungal activity of B. pyrrocinia JK-SH007. These findings provide new insights into the various biological functions regulated by CysB in B. pyrrocinia JK-SH007 and the relationship between iron-sulfur metabolic pathways and fungal inhibitory substances. Additionally, they lay the foundation for further investigation of the main antagonistic substances of B. pyrrocinia JK-SH007.


Asunto(s)
Complejo Burkholderia cepacia , Burkholderia , Antifúngicos/farmacología , Antifúngicos/metabolismo , Sideróforos/farmacología , Sideróforos/metabolismo , Cisteína/metabolismo , Burkholderia/genética , Complejo Burkholderia cepacia/metabolismo , Hierro/metabolismo , Azufre/metabolismo , Proteínas Bacterianas/metabolismo
5.
Lett Appl Microbiol ; 76(2)2023 Feb 16.
Artículo en Inglés | MEDLINE | ID: mdl-36794884

RESUMEN

The bacterial endophytes isolated from the halophyte Salicornia brachiata were explored for the antimicrobial potential to discover novel microbial inhibitors that combat multidrug resistance. Upon investigation, ethyl acetate extract of the endophyte Bacillus subtilis NPROOT3 displayed significant potency against Mycobacterium smegmatis MTCC6 as well as Mycobacterium tuberculosis H37Rv strain. Further investigation of ethyl acetate crude extract by repeated chromatographic separations followed by characterization using UV, HR-ESI-MS, MALDI-MS, MALDI-MS/MS, CD, and NMR spectroscopy yielded a series of five known siderophores, namely, SVK21 (1), bacillibactin C (2), bacillibactin B (3), tribenglthin A (4), and bacillibactin (5). A total of two out of five compounds, 4 (MIC 38.66 µM) and 5 (MIC 22.15 µM) exhibited significant inhibition against the strain M. smegmatis MTCC6 comparable with positive control rifampicin (MIC 12.15 µM). None of these five bacillibactin molecules are previously reported to exhibit bioactivity against Mycobacterium sp. Herein for the first time, all the compounds were screened for their antibacterial activities against a panel of bacterial pathogens of humans. Furthermore, the probable mechanism of action of bacillibactin compounds for their antimycobacterial activity is also discussed. The findings of this study open up a new chemotype for inhibition of the Mycobacterium sp. and other multidrug-resistant pathogens.


Asunto(s)
Mycobacterium tuberculosis , Sideróforos , Humanos , Sideróforos/farmacología , Antibacterianos/farmacología , Antibacterianos/química , Endófitos , Bacillus subtilis , Espectrometría de Masas en Tándem , Pruebas de Sensibilidad Microbiana , Extractos Vegetales/farmacología
6.
Microbiol Spectr ; 10(3): e0112122, 2022 06 29.
Artículo en Inglés | MEDLINE | ID: mdl-35674440

RESUMEN

Fungal diseases have become a major public health issue worldwide. Increasing drug resistance and the limited number of available antifungals result in high morbidity and mortality. Metal-based drugs have been reported to be therapeutic agents against major protozoan diseases, but knowledge of their ability to function as antifungals is limited. In this study, we found that calcium supplementation combined with iron deficiency causes dramatic growth inhibition of the human fungal pathogens Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans. Calcium induces the downregulation of iron uptake-related genes and, in particular, causes a decrease in the expression of the transcription factor HapX, which tends to transcriptionally activate siderophore-mediated iron acquisition under iron-deficient conditions. Iron deficiency causes calcium overload and the overproduction of intracellular reactive oxygen species (ROS), and perturbed ion homeostasis suppresses fungal growth. These phenomena are consistently identified in azole-resistant A. fumigatus isolates. The findings here imply that low iron availability lets cells mistakenly absorb calcium as a substitute, causing calcium abnormalities. Thus, there is a mutual effect between iron and calcium in fungal pathogens, and the combination of calcium with an iron chelator could serve to improve antifungal therapy. IMPORTANCE Millions of immunocompromised people are at a higher risk of developing different types of severe fungal diseases. The limited number of antifungals and the emergence of antimicrobial resistance highlight an urgent need for new strategies against invasive fungal infections. Here, we report that calcium can interfere with iron absorption of fungal pathogens, especially in iron-limited environments. Thus, a combination of calcium supplementation with an iron chelator inhibits the growth of human fungal pathogens, including Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans. Moreover, we demonstrate that iron deficiency induces a nonspecific calcium uptake response, which results in toxic levels of metal. Findings in this study suggest that a microenvironment with excess calcium and limited iron is an efficient strategy to curb the growth of fungal pathogens, especially for drug-resistant isolates.


Asunto(s)
Criptococosis , Cryptococcus neoformans , Deficiencias de Hierro , Micosis , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Aspergillus fumigatus , Calcio/metabolismo , Calcio/farmacología , Calcio/uso terapéutico , Candida albicans/metabolismo , Cryptococcus neoformans/metabolismo , Suplementos Dietéticos , Farmacorresistencia Fúngica , Humanos , Hierro/metabolismo , Micosis/microbiología , Sideróforos/metabolismo , Sideróforos/farmacología , Sideróforos/uso terapéutico
7.
Phytopathology ; 112(10): 2099-2109, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35536116

RESUMEN

Potato production worldwide is plagued by several disease-causing pathogens that result in crop and economic losses estimated to billions of dollars each year. To this day, synthetic chemical applications remain the most widespread control strategy despite their negative effects on human and environmental health. Therefore, obtainment of superior biocontrol agents or their naturally produced metabolites to replace fungicides or to be integrated into practical pest management strategies has become one of the main targets in modern agriculture. Our main focus in the present study was to elucidate the antagonistic potential of a new strain identified as Bacillus subtilis EG21 against potato pathogens Phytophthora infestans and Rhizoctonia solani using several in vitro screening assays. Microscopic examination of the interaction between EG21 and R. solani showed extended damage in fungal mycelium, while EG21 metabolites displayed strong anti-oomycete and zoosporecidal effect on P. infestans. Mass spectrometry (MS) analysis revealed that EG21 produced antifungal and anti-oomycete cyclic lipopeptides surfactins (C12 to C19). Further characterization of EG21 confirmed its ability to produce siderophores and the extracellular lytic enzymes cellulase, pectinase and chitinase. The antifungal activity of EG21 cell-free culture filtrate (CF) was found to be stable at high-temperature/pressure treatment and extreme pH values and was not affected by proteinase K treatment. Disease-inhibiting effect of EG21 CF against P. infestans and R. solani infection was confirmed using potato leaves and tubers, respectively. Biotechnological applications of using microbial agents and their bioproducts for crop protection hold great promise to develop into effective, environment-friendly and sustainable biocontrol strategies. [Formula: see text] Copyright © 2022 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.


Asunto(s)
Celulasas , Quitinasas , Fungicidas Industriales , Phytophthora infestans , Solanum tuberosum , Antifúngicos/metabolismo , Antifúngicos/farmacología , Bacillus subtilis/química , Bacillus subtilis/metabolismo , Celulasas/metabolismo , Celulasas/farmacología , Quitinasas/metabolismo , Endopeptidasa K/metabolismo , Endopeptidasa K/farmacología , Fungicidas Industriales/metabolismo , Fungicidas Industriales/farmacología , Humanos , Lipopéptidos/química , Lipopéptidos/metabolismo , Lipopéptidos/farmacología , Enfermedades de las Plantas/microbiología , Enfermedades de las Plantas/prevención & control , Poligalacturonasa/metabolismo , Rhizoctonia , Sideróforos/metabolismo , Sideróforos/farmacología , Solanum tuberosum/microbiología
8.
J Appl Microbiol ; 133(3): 1414-1421, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-35639018

RESUMEN

AIMS: To test the effect of zinc oxide nanoparticle (ZnO-NP) supplementation for enhancing the efficacy of Pseudomonas fluorescens NK4 siderophore as a biocontrol agent against P. viridiflava NK2 and a plant growth promoter. METHODS AND RESULTS: Cucumber seedlings were treated with a suspension of P. fluorescens NK4 and its siderophore generated in siderophore-inducing medium (SIM), SIM supplemented with ZnO-NP (<100 nm) and SIM supplemented with Zn2+ ions from Zn(NO3 )2 . Supplementing SIM with ZnO-NP increased siderophore secretion in P. fluorescens NK4, and irrigation of cucumber seedlings with a filtrate containing the ZnO-NP-supplemented siderophore increased survival, improved vegetative and root growth, and thus increased yield similar to the effects of dipping seedlings in a P. fluorescens NK4 suspension. Both P. fluorescens NK4 and its ZnO-NP-supplemented siderophore inhibited P. viridiflava NK2 population growth in planta. CONCLUSIONS: The siderophore of P. fluorescens NK4 produced by ZnO-NP supplementation can be employed as a biocontrol agent and biofertilizer. SIGNIFICANCE AND IMPACT OF THE STUDY: ZnO-NPs can boost the synthesis of siderophores, which can then be employed as biofertilizers to boost iron bioavailability in iron-deficient soils.


Asunto(s)
Cucumis sativus , Pseudomonas fluorescens , Óxido de Zinc , Hierro , Sideróforos/farmacología , Óxido de Zinc/farmacología
9.
Chinese Journal of Biotechnology ; (12): 990-1003, 2022.
Artículo en Chino | WPRIM | ID: wpr-927758

RESUMEN

Antimicrobial resistance is one of the critical public health issues in the world. There is an urgent need to develop effective broad-spectrum antibiotics to treat the infection of multi-drug resistant Gram-negative bacilli. Cefiderocol, developed by the Shionogi Inc. in Japan, is a new type of iron carrier cephalosporin antibiotics, which overcomes the drug resistance of Gram-negative bacilli due to the down-regulation of outer membrane pore protein and the up-regulation of efflux pump, and has good stability to serine- and metallo-carbapenemases. This drug has a broad spectrum and strong antibacterial activity against carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. Cefiderocol can be used to treat complex urinary tract infections (including pyelonephritis), hospital-acquired pneumonia, and ventilator-associated pneumonia. By summarizing the chemical structure, antibacterial mechanism, in vitro antibacterial activity, pharmacokinetics, pharmacodynamics, and clinical treatment of cefiderocol, this review shows the application potential of cefiderocol as a new iron carrier cephalosporin in the treatment of multi-drug resistant Gram-negative bacilli infections.


Asunto(s)
Cefalosporinas/uso terapéutico , Bacterias Gramnegativas , Pruebas de Sensibilidad Microbiana , Sideróforos/farmacología
10.
PLoS One ; 16(6): e0253475, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34161397

RESUMEN

Hepcidin is a peptide hormone that targets the iron exporter ferroportin, thereby limiting iron entry into the bloodstream. It is generated in hepatocytes mainly in response to increased body iron stores or inflammatory cues. Iron stimulates expression of bone morphogenetic protein 6 (BMP6) from liver sinusoidal endothelial cells, which in turn binds to BMP receptors on hepatocytes and induces the SMAD signaling cascade for transcriptional activation of the hepcidin-encoding HAMP mRNA. SMAD signaling is also essential for inflammatory HAMP mRNA induction by the IL-6/STAT3 pathway. Herein, we utilized human Huh7 hepatoma cells and primary murine hepatocytes to assess the effects of iron perturbations on signaling to hepcidin. Iron chelation appeared to slightly impair signaling to hepcidin. Subsequent iron supplementation not only failed to reverse these effects, but drastically reduced basal HAMP mRNA and inhibited HAMP mRNA induction by BMP6 and/or IL-6. Thus, treatment of cells with excess iron inhibited basal and BMP6-mediated SMAD5 phosphorylation and induction of HAMP, ID1 and SMAD7 mRNAs in a dose-dependent manner. Iron also inhibited IL-6-mediated STAT3 phosphorylation and induction of HAMP and SOCS3 mRNAs. These responses were accompanied by induction of GCLC and HMOX1 mRNAs, known markers of oxidative stress. We conclude that hepatocellular iron overload suppresses hepcidin by inhibiting the SMAD and STAT3 signaling pathways downstream of their respective ligands.


Asunto(s)
Deferoxamina/farmacología , Hepatocitos/metabolismo , Hepcidinas/metabolismo , Sobrecarga de Hierro/metabolismo , Sideróforos/farmacología , Transducción de Señal/efectos de los fármacos , Animales , Proteína Morfogenética Ósea 6/farmacología , Línea Celular Tumoral , Hepatocitos/efectos de los fármacos , Humanos , Interleucina-6/farmacología , Ratones , Fosforilación/efectos de los fármacos , Factor de Transcripción STAT3/metabolismo , Proteínas Smad/metabolismo
11.
Int J Mol Sci ; 22(2)2021 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-33419059

RESUMEN

Interest has grown in harnessing biological agents for cancer treatment as dynamic vectors with enhanced tumor targeting. While bacterial traits such as proliferation in tumors, modulation of an immune response, and local secretion of toxins have been well studied, less is known about bacteria as competitors for nutrients. Here, we investigated the use of a bacterial strain as a living iron chelator, competing for this nutrient vital to tumor growth and progression. We established an in vitro co-culture system consisting of the magnetotactic strain Magnetospirillum magneticum AMB-1 incubated under hypoxic conditions with human melanoma cells. Siderophore production by 108 AMB-1/mL in human transferrin (Tf)-supplemented media was quantified and found to be equivalent to a concentration of 3.78 µM ± 0.117 µM deferoxamine (DFO), a potent drug used in iron chelation therapy. Our experiments revealed an increased expression of transferrin receptor 1 (TfR1) and a significant decrease of cancer cell viability, indicating the bacteria's ability to alter iron homeostasis in human melanoma cells. Our results show the potential of a bacterial strain acting as a self-replicating iron-chelating agent, which could serve as an additional mechanism reinforcing current bacterial cancer therapies.


Asunto(s)
Deferoxamina/farmacología , Magnetospirillum/metabolismo , Neoplasias/tratamiento farmacológico , Receptores de Transferrina/metabolismo , Transferrina/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Humanos , Quelantes del Hierro/farmacología , Neoplasias/metabolismo , Neoplasias/patología , Sideróforos/metabolismo , Sideróforos/farmacología
12.
Cell Chem Biol ; 27(12): 1532-1543.e6, 2020 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-33186541

RESUMEN

Pioneering microbial genomic surveys have revealed numerous untapped biosynthetic gene clusters, unveiling the great potential of new natural products. Here, using a combination of genome mining, mutasynthesis, and activity screening in an infection model comprising Caenorhabditis elegans and Pseudomonas aeruginosa, we identified candidate virulence-blocking amychelin siderophore compounds from actinomycetes. Subsequently, we developed unreported analogs of these virulence-blocking siderophores with improved potency by exploiting an Amycolatopsis methanolica strain 239T chorismate to salicylate a biosynthetic subpathway for mutasynthesis. This allowed us to generate the fluorinated amychelin, fluoroamychelin I, which rescued C. elegans from P. aeruginosa-mediated killing with an EC50 value of 1.4 µM, outperforming traditional antibiotics including ceftazidime and meropenem. In general, this paper describes an efficient platform for the identification and production of classes of anti-microbial compounds with potential unique modes of action.


Asunto(s)
Minería de Datos , Genómica , Halogenación , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/genética , Sideróforos/química , Sideróforos/farmacología , Animales , Antibacterianos/química , Antibacterianos/farmacología , Caenorhabditis elegans/genética , Ceftazidima/farmacología , Evaluación Preclínica de Medicamentos , Meropenem/farmacología
13.
Clin Drug Investig ; 40(10): 901-913, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32700154

RESUMEN

Cefiderocol (Fetroja®) is a siderophore cephalosporin and has demonstrated potent activity against extended-spectrum beta-lactamases producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii, Burkholderia cepacia, and Klebsiella pneumoniae. However, cefiderocol has limited activity against Gram-positive bacteria and anaerobes like Bacterodies fragilis. In the APEKS-cUTI study, 183 (73%) of 252 patients in the cefiderocol group versus 65 (55%) of 119 patients in the imipenem-cilastatin group achieved the composite outcome of clinical and microbiological eradication of Gram-negative bacteria (treatment difference of 18.58%; 95% CI 8.23-28.92, p = 0.0004) in complicated urinary tract infections (cUTIs). Cefiderocol was non-inferior to imipenem-cilastatin in cUTIs caused by Gram-negative bacteria such as E. coli, K. pneumoniae, P. aeruginosa, Proteus mirabilis, Enterobacter cloacae, Morganella morganii, and Citrobacter freundii. Cefiderocol required dose adjustment in patients with renal impairment and percentage of time that free drug concentrations above the minimum inhibitory concentration (%fT > MIC) best correlated with clinical outcomes. The most common adverse events with cefiderocol were gastrointestinal symptoms such as diarrhea, constipation, nausea, vomiting, or upper abdominal pain. Two phase III clinical trials, the CREDIBLE-CR study and the APEKS-NP study, investigated the efficacy and safety of cefiderocol for the treatment of pneumonia or cUTI, and both studies showed higher all-cause mortality associated with cefiderocol. Therefore, the use of cefiderocol should be limited only to the treatment of cUTIs from Gram-negative bacteria, especially in patients who have limited or no alternative treatment options.


Asunto(s)
Antibacterianos/uso terapéutico , Cefalosporinas/uso terapéutico , Bacterias Gramnegativas/efectos de los fármacos , Sideróforos/farmacología , Infecciones Urinarias/tratamiento farmacológico , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Cefalosporinas/farmacocinética , Cefalosporinas/farmacología , Humanos , Pruebas de Sensibilidad Microbiana , Infecciones Urinarias/microbiología , Cefiderocol
14.
J Microbiol Biotechnol ; 30(5): 689-699, 2020 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-32482934

RESUMEN

Brevibacillus brevis GZDF3 is a gram-positive, plant growth-promoting rhizosphere bacterium (PGPR) isolated from the rhizosphere soil of Pinellia ternata (an important herb in traditional Chinese medicine). The GZDF3 strain produces certain active compounds, such as siderophores, which are the final metabolite products of non-ribosomal peptide synthetase (NRPS) and independent non-ribosomal peptide synthetase (NIS) activity. With the present study, we attempted to investigate the siderophore production characteristics and conditions of Bacillus sp. GZDF3. The antibacterial activity of the siderophores on pathogenic fungi was also investigated. Optimal conditions for the synthesis of siderophores were determined by single factor method, using sucrose 15 g/l, asparagine 2 g/l, 32°C, and 48 h. The optimized sucrose asparagine medium significantly increased the production of siderophores, from 27.09% to 54.99%. Moreover, the effects of different kinds of metal ions on siderophore production were explored here. We found that Fe3+ and Cu2+ significantly inhibited the synthesis of siderophores. The preliminary separation and purification of siderophores by immobilized-metal affinity chromatography (IMAC) provides strong antibacterial activity against Candida albicans. The synergistic effect of siderophores and amphotericin B was also demonstrated. Our results have shown that the GZDF3 strain could produce a large amount of siderophores with strong antagonistic activity, which is helpful in the development of new biological control agents.


Asunto(s)
Antifúngicos , Brevibacillus/metabolismo , Candida albicans/efectos de los fármacos , Pinellia/microbiología , Sideróforos , Antifúngicos/metabolismo , Antifúngicos/farmacología , Brevibacillus/aislamiento & purificación , Medios de Cultivo , Rizosfera , Sideróforos/metabolismo , Sideróforos/farmacología
15.
J Musculoskelet Neuronal Interact ; 20(1): 121-127, 2020 03 03.
Artículo en Inglés | MEDLINE | ID: mdl-32131376

RESUMEN

OBJECTIVE: The rise in primary and revision surgeries utilizing joint replacement implants suggest the need for more reliable means of promoting implant fixation. Zoledronate-(Zol), cytochalasin-D-(cytoD), and desferrioxamine-(DFO) have been shown to enhance mesenchymal stem cell (MSC) differentiation into osteoblasts promoting bone formation. The objective was to determine whether Zol, cytoD, and DFO can improve fixation strength and enhance peri-implant bone volume about intra-medullary femoral implants. METHODS: 48 Sprague-Dawley female rats were randomized into four treatments, saline-control or experimental: Zol-(0.8 µg/µL), cytoD-(0.05 µg/µL), DFO-(0.4 µg/µL). Implants were placed bilaterally in the femoral canals following injection of treatment solution and followed for 28 days. Mechanical push-out testing and micro-CT were our primary evaluations, measuring load to failure and bone volume. Qualitative evaluation included histological assessment. Data was analyzed with a one-way ANOVA with Holm-Sidak mean comparison testing. RESULTS: Significant results included pushout tests showing an increase in maximum energy for Zol (124%) and cytoD (82%); Zol showed an increase in maximum load by 48%; Zol micro-CT showed increase in BV/TV by 35%. CONCLUSIONS: Our findings suggest that locally applied Zol and cytoD enhance implant mechanical stability. Bisphosphonates and actin regulators, like cytoD, might be further investigated as a new strategy for improving osseointegration.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Prótesis Anclada al Hueso , Citocalasina D/farmacología , Deferoxamina/farmacología , Fémur/diagnóstico por imagen , Ácido Zoledrónico/farmacología , Animales , Evaluación Preclínica de Medicamentos/métodos , Femenino , Fémur/efectos de los fármacos , Fémur/cirugía , Modelos Animales , Inhibidores de la Síntesis del Ácido Nucleico/farmacología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Sideróforos/farmacología
16.
Leuk Res ; 77: 17-27, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30612055

RESUMEN

Tropolones are naturally occurring seven-membered non-benzenoid aromatic compounds that are of interest due to their cytotoxic properties. MO-OH-Nap is a novel α-substituted tropolone that induces caspase cleavage and upregulates markers associated with the unfolded protein response (UPR) in multiple myeloma (MM) cells. Given previous reports that tropolones may function as iron chelators, we investigated the effects of MO-OH-Nap, as well as the known iron chelator deferoxamine (DFO), in MM cells in the presence or absence of supplemental iron. The ability of MO-OH-Nap to induce apoptosis and upregulate markers of the UPR could be completely prevented by co-incubation with either ferric chloride or ammonium ferrous sulfate. Iron also completely prevented the decrease in BrdU incorporation induced by either DFO or MO-OH-Nap. Ferrozine assays demonstrated that MO-OH-Nap directly chelates iron. Furthermore, MO-OH-Nap upregulates cell surface expression and mRNA levels of transferrin receptor. In vivo studies demonstrate increased Prussian blue staining in hepatosplenic macrophages in MO-OH-Nap-treated mice. These studies demonstrate that MO-OH-Nap-induced cytotoxic effects in MM cells are dependent on the tropolone's ability to alter cellular iron availability and establish new connections between iron homeostasis and the UPR in MM.


Asunto(s)
Apoptosis/efectos de los fármacos , Quelantes del Hierro/farmacología , Hierro/metabolismo , Mieloma Múltiple/patología , Receptores de Transferrina/metabolismo , Tropolona/farmacología , Respuesta de Proteína Desplegada/efectos de los fármacos , Animales , Ciclo Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Cloruros/farmacología , Deferoxamina/farmacología , Femenino , Compuestos Férricos/farmacología , Compuestos Ferrosos/farmacología , Humanos , Ratones , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/metabolismo , Compuestos de Amonio Cuaternario/farmacología , Sideróforos/farmacología , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
17.
ACS Nano ; 12(5): 4123-4139, 2018 05 22.
Artículo en Inglés | MEDLINE | ID: mdl-29617109

RESUMEN

Excess iron deposition in the brain often causes oxidative stress-related damage and necrosis of dopaminergic neurons in the substantia nigra and has been reported to be one of the major vulnerability factors in Parkinson's disease (PD). Iron chelation therapy using deferoxamine (DFO) may inhibit this nigrostriatal degeneration and prevent the progress of PD. However, DFO shows very short half-life in vivo and hardly penetrates the blood brain barrier (BBB). Hence, it is of great interest to develop DFO formulations for safe and efficient intracerebral drug delivery. Herein, we report a polymeric nanoparticle system modified with brain-targeting peptide rabies virus glycoprotein (RVG) 29 that can intracerebrally deliver DFO. The nanoparticle system penetrates the BBB possibly through specific receptor-mediated endocytosis triggered by the RVG29 peptide. Administration of these nanoparticles significantly decreased iron content and oxidative stress levels in the substantia nigra and striatum of PD mice and effectively reduced their dopaminergic neuron damage and as reversed their neurobehavioral deficits, without causing any overt adverse effects in the brain or other organs. This DFO-based nanoformulation holds great promise for delivery of DFO into the brain and for realizing iron chelation therapy in PD treatment.


Asunto(s)
Encéfalo/metabolismo , Deferoxamina/administración & dosificación , Sistemas de Liberación de Medicamentos , Glicoproteínas/química , Nanopartículas/administración & dosificación , Nanopartículas/metabolismo , Enfermedad de Parkinson/tratamiento farmacológico , Fragmentos de Péptidos/química , Proteínas Virales/química , Animales , Encéfalo/efectos de los fármacos , Deferoxamina/farmacocinética , Deferoxamina/farmacología , Deferoxamina/uso terapéutico , Glicoproteínas/administración & dosificación , Masculino , Ratones , Ratones Endogámicos C57BL , Enfermedad de Parkinson/metabolismo , Fragmentos de Péptidos/administración & dosificación , Sideróforos/administración & dosificación , Sideróforos/farmacocinética , Sideróforos/farmacología , Sideróforos/uso terapéutico , Proteínas Virales/administración & dosificación
18.
Int J Mol Sci ; 18(12)2017 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-29261151

RESUMEN

Iron overload (IOL) due to increased intestinal iron absorption constitutes a major clinical problem in patients with non-transfusion-dependent thalassemia (NTDT), which is a cumulative process with advancing age. Current models for iron metabolism in patients with NTDT suggest that suppression of serum hepcidin leads to an increase in iron absorption and subsequent release of iron from the reticuloendothelial system, leading to depletion of macrophage iron, relatively low levels of serum ferritin, and liver iron loading. The consequences of IOL in patients with NTDT are multiple and multifactorial. Accurate and reliable methods of diagnosis and monitoring of body iron levels are essential, and the method of choice for measuring iron accumulation will depend on the patient's needs and on the available facilities. Iron chelation therapy (ICT) remains the backbone of NTDT management and is one of the most effective and practical ways of decreasing morbidity and mortality. The aim of this review is to describe the mechanism of IOL in NTDT, and the clinical complications that can develop as a result, in addition to the current and future therapeutic options available for the management of IOL in NTDT.


Asunto(s)
Sobrecarga de Hierro/tratamiento farmacológico , Sideróforos/uso terapéutico , Talasemia/tratamiento farmacológico , Ensayos Clínicos como Asunto , Humanos , Hierro/metabolismo , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/etiología , Sideróforos/administración & dosificación , Sideróforos/efectos adversos , Sideróforos/farmacología , Talasemia/complicaciones
19.
PLoS One ; 12(8): e0182302, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28771547

RESUMEN

Plant growth promoting rhizobacteria (PGPR) are studied in different agricultural crops but the interaction of PGPR of tea crop is not yet studied well. In the present study, the indigenous tea rhizobacteria were isolated from seven tea estates of Darjeeling located in West Bengal, India. A total of 150 rhizobacterial isolates were screened for antagonistic activity against six different fungal pathogens i.e. Nigrospora sphaerica (KJ767520), Pestalotiopsis theae (ITCC 6599), Curvularia eragostidis (ITCC 6429), Glomerella cingulata (MTCC 2033), Rhizoctonia Solani (MTCC 4633) and Fusarium oxysporum (MTCC 284), out of which 48 isolates were antagonist to at least one fungal pathogen used. These 48 isolates exhibited multifarious antifungal properties like the production of siderophore, chitinase, protease and cellulase and also plant growth promoting (PGP) traits like IAA production, phosphate solubilization, ammonia and ACC deaminase production. Amplified ribosomal DNA restriction analysis (ARDRA) and BOX-PCR analysis based genotyping clustered the isolates into different groups. Finally, four isolates were selected for plant growth promotion study in two tea commercial cultivars TV-1 and Teenali-17 in nursery conditions. The plant growth promotion study showed that the inoculation of consortia of these four PGPR isolates significantly increased the growth of tea plant in nursery conditions. Thus this study underlines the commercial potential of these selected PGPR isolates for sustainable tea cultivation.


Asunto(s)
Alphaproteobacteria/clasificación , Alphaproteobacteria/metabolismo , Camellia sinensis/crecimiento & desarrollo , Camellia sinensis/microbiología , Filogenia , Alphaproteobacteria/aislamiento & purificación , Amoníaco/metabolismo , Antifúngicos/metabolismo , Antifúngicos/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Fosfatos de Calcio/metabolismo , Liasas de Carbono-Carbono/metabolismo , Celulasa/genética , Celulasa/metabolismo , Quitinasas/genética , Quitinasas/metabolismo , ADN de Hongos/aislamiento & purificación , ADN de Hongos/metabolismo , Hongos/efectos de los fármacos , Genotipo , Glicósido Hidrolasas/genética , Glicósido Hidrolasas/metabolismo , India , Ácidos Indolacéticos/metabolismo , Raíces de Plantas/crecimiento & desarrollo , Raíces de Plantas/microbiología , ARN Ribosómico 16S/clasificación , ARN Ribosómico 16S/aislamiento & purificación , ARN Ribosómico 16S/metabolismo , Sideróforos/metabolismo , Sideróforos/farmacología , Microbiología del Suelo
20.
ACS Infect Dis ; 3(7): 542-553, 2017 07 14.
Artículo en Inglés | MEDLINE | ID: mdl-28505405

RESUMEN

Staphylococcus aureus produces a cocktail of metallophores (staphylopine, staphyloferrin A, and staphyloferrin B) to scavenge transition metals during infection of a host. In addition, S. aureus displays the extracellular surface lipoproteins FhuD1 and FhuD2 along with the ABC transporter complex FhuCBG to facilitate the use of hydroxamate xenosiderophores such as desferrioxamine B (DFOB) for iron acquisition. DFOB is used as a chelation therapy to treat human iron overload diseases and has been linked to an increased risk of S. aureus infections. We used a panel of synthetic DFOB analogs and a FhuD2-selective trihydroxamate sideromycin to probe xenosiderophore utilization in S. aureus and establish structure-activity relationships for Fe(III) binding, FhuD2 binding, S. aureus growth promotion, and competition for S. aureus cell entry. Fe(III) binding assays and FhuD2 intrinsic fluorescence quenching experiments revealed that diverse chemical modifications of the terminal ends of linear ferrioxamine siderophores influences Fe(III) affinity but not FhuD2 binding. Siderophore-sideromycin competition assays and xenosiderophore growth promotion assays revealed that S. aureus SG511 and ATCC 11632 can distinguish between competing siderophores based exclusively on net charge of the siderophore-Fe(III) complex. Our work provides a roadmap for tuning hydroxamate xenosiderophore scaffolds to suppress (net negative charge) or enhance (net positive or neutral charge) uptake by S. aureus for applications in metal chelation therapy and siderophore-mediated antibiotic delivery, respectively.


Asunto(s)
Deferoxamina/metabolismo , Hierro/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Staphylococcus aureus Resistente a Meticilina/metabolismo , Proteínas de Unión Periplasmáticas/metabolismo , Sideróforos/metabolismo , Unión Competitiva , Cationes , Deferoxamina/análogos & derivados , Deferoxamina/farmacología , Expresión Génica , Cinética , Proteínas de Transporte de Membrana/genética , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/genética , Modelos Moleculares , Proteínas de Unión Periplasmáticas/genética , Unión Proteica , Sideróforos/síntesis química , Sideróforos/farmacología , Electricidad Estática , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA